Primary Sjögren Syndrome Clinical Trial
Official title:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Intravenous RSLV-132 in Participants With Primary Sjögren's Syndrome (pSS) With Moderate to Severe Symptom Burden
The goal of this clinical study is to learn if RSLV-132 improves the symptoms of pSS in adults. It will also learn about the safety of RSLV-132. The main questions it aims to answer are: - Does RSLV-132 improve the cardinal symptoms of Sjogren's including fatigue, dryness and pain? - Does RSLV-132 improve the tiredness/fatigue caused by Sjogren's? - What are the blood levels of RSLV-132 over time? - What is the immune (antibody) response in the body to RSLV-132? - What is the safety profile of RSLV-132? Researchers will compare RSLV-132 to a placebo (a look-alike substance that contains no drug) to see if RSLV-132 improves the symptoms of pSS. Participants will: Take RSLV-132 or a placebo 13 times over 22 weeks Visit the clinic once every week for the first 2 weeks, then every 2 weeks until the end of treatment and then for a final time 4 weeks later (Day 211) for check-ups, tests and to answer questionnaires about their symptoms Record their symptoms every day on an electronic device
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03140111 -
LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients
|
N/A | |
Not yet recruiting |
NCT06049368 -
68Ga-P16-093 PET/CT Imaging in the Salivary Gland
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03614299 -
Eye Dryness Evaluation in Primary Sjögren's Syndrome
|
||
Not yet recruiting |
NCT03126383 -
Inflammatory Myopathies in Primary Sjögren's Syndrome
|
N/A | |
Recruiting |
NCT04830644 -
A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.
|
Phase 2 | |
Not yet recruiting |
NCT03765593 -
Biomarkers in Primary Sjögren's Syndrome
|
||
Completed |
NCT01081184 -
Neurotrophins Implications in Primary Sjögren Syndrome
|
N/A | |
Completed |
NCT05670535 -
Sjögren and Gynecologic Considerations
|
||
Completed |
NCT03226444 -
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
|
Phase 1/Phase 2 | |
Completed |
NCT04816370 -
Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions
|
N/A | |
Completed |
NCT05380804 -
Cutaneous Silent Period Assessment in Primary Sjögren's Syndrome
|
||
Terminated |
NCT04700280 -
A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 12 Weeks in Adults With Active Primary Sjögren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT03130062 -
Resistance Exercise in Woman With Primary Sjörgen Syndrome.
|
N/A | |
Completed |
NCT04093531 -
Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome
|
Phase 1 | |
Recruiting |
NCT03509064 -
Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy
|
||
Completed |
NCT04224454 -
Vaccine Coverage and Primary Sjögren'Syndrome
|
||
Completed |
NCT04960605 -
Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome
|
N/A | |
Recruiting |
NCT06361745 -
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
N/A |